DK2860251T3 - Aptapmer-lægemidler nyttige ved behandling af komplement-relaterede lidelser - Google Patents
Aptapmer-lægemidler nyttige ved behandling af komplement-relaterede lidelser Download PDFInfo
- Publication number
- DK2860251T3 DK2860251T3 DK14194459.5T DK14194459T DK2860251T3 DK 2860251 T3 DK2860251 T3 DK 2860251T3 DK 14194459 T DK14194459 T DK 14194459T DK 2860251 T3 DK2860251 T3 DK 2860251T3
- Authority
- DK
- Denmark
- Prior art keywords
- aptamer
- seq
- nucleotides
- complement
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
Claims (16)
1. Aptamer eller et salt deraf, hvor aptameren er: fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfC fCfUmGfCmG-3T (SEQ ID NO: 4), hvor fC og fU = 2'-fluor-nukleotider, mG og mA = 2'-OMe-nukleotider, og alle andre nukleotider er 2'-OH, og 3T angiver en inverteret deoxythymidin.
2. Sammensætning omfattende en terapeutisk virkningsfuld mængde af aptameren eller saltet deraf ifølge krav 1 og en farmaceutisk acceptabel bærer eller et farmaceutisk acceptabelt fortyndingsmiddel.
3. Anvendelse af aptamer eller salt deraf ifølge krav 1 til fremstilling af et lægemiddel til behandling, forebyggelse eller lindring af en sygdom medieret af C5-, C5a- og/eller C5b-9-komplementprotein hos et pattedyr.
4. Aptamer eller salt deraf ifølge krav 1 til anvendelse i en fremgangsmåde til behandling, forebyggelse eller lindring af en sygdom medieret af C5-, C5a- og/eller C5b-9-komplementprotein hos et pattedyr.
5. Anvendelse ifølge krav 3, eller aptameren eller saltet deraf til anvendelse i en fremgangsmåde til behandling, forebyggelse eller lindring af en sygdom medieret af C5-, C5a- og/eller C5b-9-komplementprotein i et pattedyr ifølge krav 4, hvor pattedyret er et menneske.
6. Anvendelse ifølge krav 3, eller aptameren eller saltet deraf til anvendelse i en fremgangsmåde til behandling, forebyggelse eller lindring af en sygdom medieret af C5-, C5a- og/eller C5b-9-komplementprotein i et pattedyr ifølge krav 4, hvor sygdommen er en akut iskæmisk sygdom, en akut inflammatorisk sygdom eller en kronisk inflammatorisk eller immun-medieret sygdom.
7. Anvendelse ifølge krav 3, eller aptameren eller saltet deraf til anvendelse i en fremgangsmåde til behandling, forebyggelse eller lindring af en sygdom medieret af C5-, C5a- og/eller C5b-9-komplementprotein i et pattedyr ifølge krav 4, hvor sygdommen er myokardieinfarkt, slagtilfælde, iskæmi/reperfusionsskade, infektionssygdom, septikæmi, chok, akut transplantatafvisning, hyperakut transplantatafvisning, allergi, astma, reumato-id arthritis eller anden reumatologisk sygdom, multipel sklerose eller anden neurologisk sygdom, psoriasis eller anden dermatologisk sygdom, myastheni gravis, systemisk lupus erythematosus (SLE), subakut transplantatafvisning, kronisk transplantatafvisning eller glomerulonefritis eller anden nyresygdom.
8. Anvendelse ifølge krav 3, eller aptameren eller saltet deraf til anvendelse i en fremgangsmåde til behandling, forebyggelse eller lindring af en sygdom medieret af C5-, C5a- og/eller C5b-9-komplementprotein i et pattedyr ifølge krav 4, hvor sygdommen er myokardieskade relateret til koronararterie bypass (CABG-) kirurgi, myokardieskade relateret til ballonangioplastik eller myokardieskade relateret til restenose.
9. Anvendelse ifølge krav 3, eller aptameren eller saltet deraf til anvendelse i en fremgangsmåde til behandling, forebyggelse eller lindring af en sygdom medieret af C5-, C5a- og/eller C5b-9-komplementprotein i et pattedyr ifølge krav 4, hvor sygdommen, der skal behandles, er en C5-, C5a- og/eller C5b-9-komplementprotein-medieret komplikation relateret til CABG-kirurg i.
10. Anvendelse ifølge krav 8 eller 9, eller aptameren eller saltet deraf til anvendelse i en fremgangsmåde til behandling, forebyggelse eller lindring af en sygdom medieret af C5-, C5a- og/eller C5b-9-komplementprotein i et pattedyr ifølge krav 8 eller 9, hvor forbindelsen indgives forud for kirurgi og indgives kontinuerligt i mindst 24 timer.
11. Anvendelse ifølge krav 3, eller aptameren eller saltet deraf til anvendelse i en fremgangsmåde til behandling, forebyggelse eller lindring af en sygdom medieret af C5-, C5a- og/eller C5b-9-komplementprotein i et pattedyr ifølge krav 4, hvor forbindelsen indgives intravenøst.
12. In v/'tro-diagnostisk fremgangsmåde omfattende at kontakte aptameren eller saltet deraf ifølge krav 1 med en sammensætning, der mistænkes for at omfatte C5-komplementprotein eller en variant deraf, og detektere tilstedeværelsen eller fraværet af C5-komplementproteinet eller en variant deraf.
13. Diagnostisk fremgangsmåde ifølge krav 12, hvor C5-komplementproteinet eller varianten deraf er et humant C5-komplementprotein eller en variant deraf.
14. Aptamer eller et salt ifølge krav 1 til anvendelse som in v/tro-diagnostik.
15. Aptamer eller et salt ifølge krav 1 til anvendelse som in v/Vo-diagnostisk middel.
16. Aptamer eller salt ifølge krav 1 til anvendelse ved behandling, forebyggelse eller lindring af sygdommen in vivo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54454204P | 2004-02-12 | 2004-02-12 | |
| US54774704P | 2004-02-25 | 2004-02-25 | |
| US58168504P | 2004-06-21 | 2004-06-21 | |
| US60804804P | 2004-09-07 | 2004-09-07 | |
| EP13150168.6A EP2578683B9 (en) | 2004-02-12 | 2005-02-14 | Aptamer therapeutics useful in the treatment of complement-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2860251T3 true DK2860251T3 (da) | 2018-06-06 |
Family
ID=34891329
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14194459.5T DK2860251T3 (da) | 2004-02-12 | 2005-02-14 | Aptapmer-lægemidler nyttige ved behandling af komplement-relaterede lidelser |
| DK05713496.7T DK1727567T3 (da) | 2004-02-12 | 2005-02-14 | Aptamer-terapeutiske midler nyttige i behandling af komplementrelaterede forstyrrelser |
| DK18156968.2T DK3385384T3 (da) | 2004-02-12 | 2005-02-14 | Aptamer-lægemidler nyttige ved behandlingen af komplement-relaterede lidelser |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05713496.7T DK1727567T3 (da) | 2004-02-12 | 2005-02-14 | Aptamer-terapeutiske midler nyttige i behandling af komplementrelaterede forstyrrelser |
| DK18156968.2T DK3385384T3 (da) | 2004-02-12 | 2005-02-14 | Aptamer-lægemidler nyttige ved behandlingen af komplement-relaterede lidelser |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7538211B2 (da) |
| EP (5) | EP3385384B1 (da) |
| JP (1) | JP5242918B2 (da) |
| CY (3) | CY1114443T1 (da) |
| DK (3) | DK2860251T3 (da) |
| ES (4) | ES2429442T3 (da) |
| HK (2) | HK1183896A1 (da) |
| HU (2) | HUE050481T2 (da) |
| LT (2) | LT2860251T (da) |
| PL (2) | PL2860251T3 (da) |
| PT (3) | PT1727567E (da) |
| SI (2) | SI3385384T1 (da) |
| TR (1) | TR201808488T4 (da) |
| WO (1) | WO2005079363A2 (da) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| IL159053A0 (en) * | 2001-05-25 | 2004-05-12 | Univ Duke | Modulators of pharmacological agents |
| MXPA05010773A (es) | 2003-04-09 | 2005-12-12 | Neose Technologies Inc | Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos. |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| JP5948627B2 (ja) | 2004-10-29 | 2016-07-20 | レイショファーム ゲーエムベーハー | 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化 |
| EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
| US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| JP2009515508A (ja) * | 2005-08-19 | 2009-04-16 | ネオス テクノロジーズ インコーポレイテッド | グリコｐｅｇ化因子ｖｉｉおよび因子ｖｉｉａ |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| JP2009519033A (ja) * | 2005-12-16 | 2009-05-14 | ディアト | 核酸を細胞に送達するための細胞貫通ペプチド結合体 |
| MX2008011323A (es) * | 2006-03-08 | 2008-11-18 | Archemix Corp | Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares. |
| CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
| WO2008097525A2 (en) | 2007-02-05 | 2008-08-14 | Potentia Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
| US20100166748A1 (en) * | 2007-03-22 | 2010-07-01 | Novartis Ag | C5 Antigens and Uses Thereof |
| RS52845B (en) | 2007-04-03 | 2013-12-31 | Biogenerix Ag | TREATMENT PROCEDURES USING GLYCOPEGILATED G-CSF |
| WO2008134077A1 (en) * | 2007-04-30 | 2008-11-06 | Archemix Corp. | Metabolic profile directed aptamer medicinal chemistry |
| US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
| AU2008303775A1 (en) * | 2007-09-24 | 2009-04-02 | Noxxon Pharma Ag | C5a binding nucleic acids |
| BRPI0820475A2 (pt) * | 2007-11-19 | 2015-06-16 | Carefusion 2200 Inc | Sistema de terapia respiratória com acionador eletromecânico |
| WO2009073821A2 (en) * | 2007-12-04 | 2009-06-11 | Archemix Corp. | Biopolymer-nucleic acid conjugation |
| EP2257311B1 (en) | 2008-02-27 | 2014-04-16 | Novo Nordisk A/S | Conjugated factor viii molecules |
| WO2010108657A2 (en) * | 2009-03-23 | 2010-09-30 | Noxxon Pharma Ag | C5a binding nucleic acids and the use thereof |
| US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| EP2468295A1 (en) * | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
| JP6618682B2 (ja) | 2011-06-22 | 2019-12-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 補体阻害剤による慢性障害の治療方法 |
| MX362061B (es) | 2012-01-10 | 2019-01-07 | Noxxon Pharma Ag | Ácidos nucleicos de enlace c5a nuevos. |
| EP2666785A1 (en) * | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
| DK2920201T3 (da) | 2012-11-15 | 2020-04-14 | Apellis Pharmaceuticals Inc | Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| EP3473272A1 (en) | 2013-03-29 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| EP3359555B1 (en) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| EP4272821A3 (en) | 2017-04-03 | 2024-01-03 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| BR112019020955A2 (pt) | 2017-04-07 | 2020-05-05 | Apellis Pharmaceuticals Inc | regimes de dosagem e composições e métodos relacionados |
| US10450345B2 (en) | 2017-06-09 | 2019-10-22 | General Electric Company | Method of isolation of polypeptide-aptamer-polymer conjugates |
| CA3066689C (en) | 2017-06-23 | 2024-01-16 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
| RU2703799C1 (ru) * | 2018-05-31 | 2019-10-22 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Днк-аптамеры, взаимодействующие с протромбином |
| WO2021067526A1 (en) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
| AU2020438234A1 (en) | 2020-03-27 | 2022-09-29 | Inflarx Gmbh | Inhibitors of C5a for the treatment of corona virus infection |
| US20230349887A1 (en) | 2020-05-15 | 2023-11-02 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4959309A (en) | 1983-07-14 | 1990-09-25 | Molecular Diagnostics, Inc. | Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| GB2181661B (en) | 1985-10-22 | 1989-09-20 | Nat Res Dev | Improvements in or relating to apparatus for removing settled sludge from liquid |
| US4935363A (en) | 1987-03-30 | 1990-06-19 | Board Of Regents, The University Of Texas System | Sterol regulatory elements |
| WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5070010A (en) | 1989-10-30 | 1991-12-03 | Hoffman-La Roche Inc. | Method for determining anti-viral transactivating activity |
| EP0523140A4 (en) | 1990-03-21 | 1993-06-16 | Isis Pharmaceuticals, Inc. | Reagents and methods for modulating gene expression through rna mimicry |
| US5648214A (en) | 1990-06-11 | 1997-07-15 | University Research Corporation | High-affinity oligonucleotide ligands to the tachykinin substance P |
| US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5789157A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| US5459015A (en) | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5674685A (en) | 1990-06-11 | 1997-10-07 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5668264A (en) | 1990-06-11 | 1997-09-16 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US6140490A (en) * | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5861254A (en) | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
| US5635615A (en) | 1990-06-11 | 1997-06-03 | Nexstar Pharmaceuticals, Inc. | High affinity HIV nucleocapsid nucleic acid ligands |
| US5763173A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| JP2763958B2 (ja) | 1990-06-11 | 1998-06-11 | ネクスター ファーマスーティカルズ，インコーポレイテッド | 核酸リガンド |
| US5654151A (en) | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
| JPH06503715A (ja) | 1990-09-21 | 1994-04-28 | フレッド ハッチンソン キャンサー リサーチ センター | タンパク質配列特異的オリゴヌクレオチド配列 |
| CA2093664C (en) | 1990-10-12 | 2003-07-29 | Fritz Eckstein | Modified ribozymes |
| WO1992014842A1 (en) | 1991-02-21 | 1992-09-03 | Gilead Sciences, Inc. | Aptamers specific for thrombin and methods of use |
| CA2104698A1 (en) | 1991-02-21 | 1992-08-22 | John J. Toole | Aptamers specific for biomolecules and methods of making |
| WO2002081494A1 (en) * | 2001-03-26 | 2002-10-17 | Sirna Therapeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| US5338671A (en) | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
| TW239160B (da) * | 1992-10-27 | 1995-01-21 | Procter & Gamble | |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US5817635A (en) | 1993-08-09 | 1998-10-06 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| US5681702A (en) * | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
| EP1741780A3 (en) | 1995-06-02 | 2007-03-28 | Gilead Sciences, Inc. | High affinity oligonucleotide ligands to growth factors |
| US6111095A (en) * | 1995-06-07 | 2000-08-29 | Merck & Co., Inc. | Capped synthetic RNA, analogs, and aptamers |
| AU726844B2 (en) | 1995-06-07 | 2000-11-23 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands that bind to and inhibit DNA polymerases |
| US6229002B1 (en) | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| ATE318143T1 (de) | 1996-10-25 | 2006-03-15 | Gilead Sciences Inc | Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe |
| US7419663B2 (en) * | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US6329145B1 (en) * | 1999-02-09 | 2001-12-11 | Gilead Science, Inc. | Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| JP2005533794A (ja) * | 2002-06-18 | 2005-11-10 | アーケミックス コーポレイション | アプタマー−毒素分子およびこれを使用する方法 |
| US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
-
2005
- 2005-02-14 DK DK14194459.5T patent/DK2860251T3/da active
- 2005-02-14 DK DK05713496.7T patent/DK1727567T3/da active
- 2005-02-14 ES ES05713496T patent/ES2429442T3/es active Active
- 2005-02-14 EP EP18156968.2A patent/EP3385384B1/en active Active
- 2005-02-14 PT PT57134967T patent/PT1727567E/pt unknown
- 2005-02-14 ES ES14194459.5T patent/ES2674129T3/es active Active
- 2005-02-14 PL PL14194459T patent/PL2860251T3/pl unknown
- 2005-02-14 TR TR2018/08488T patent/TR201808488T4/tr unknown
- 2005-02-14 HU HUE18156968A patent/HUE050481T2/hu unknown
- 2005-02-14 DK DK18156968.2T patent/DK3385384T3/da active
- 2005-02-14 SI SI200532280T patent/SI3385384T1/sl unknown
- 2005-02-14 JP JP2006553313A patent/JP5242918B2/ja active Active
- 2005-02-14 WO PCT/US2005/004606 patent/WO2005079363A2/en active Application Filing
- 2005-02-14 EP EP13150168.6A patent/EP2578683B9/en not_active Not-in-force
- 2005-02-14 EP EP14194459.5A patent/EP2860251B1/en active Active
- 2005-02-14 ES ES13150168T patent/ES2531075T3/es active Active
- 2005-02-14 SI SI200532210T patent/SI2860251T1/en unknown
- 2005-02-14 PL PL18156968T patent/PL3385384T3/pl unknown
- 2005-02-14 PT PT181569682T patent/PT3385384T/pt unknown
- 2005-02-14 HU HUE14194459A patent/HUE038239T2/hu unknown
- 2005-02-14 EP EP20168481.8A patent/EP3736335A1/en active Pending
- 2005-02-14 PT PT141944595T patent/PT2860251T/pt unknown
- 2005-02-14 LT LTEP14194459.5T patent/LT2860251T/lt unknown
- 2005-02-14 ES ES18156968T patent/ES2808955T3/es active Active
- 2005-02-14 EP EP05713496.7A patent/EP1727567B1/en active Active
- 2005-02-14 LT LTEP18156968.2T patent/LT3385384T/lt unknown
- 2005-12-22 US US11/318,227 patent/US7538211B2/en active Active
-
2006
- 2006-02-14 US US11/354,657 patent/US7579456B2/en active Active
-
2013
- 2013-09-30 HK HK13111168.8A patent/HK1183896A1/xx unknown
- 2013-09-30 CY CY20131100843T patent/CY1114443T1/el unknown
-
2015
- 2015-10-07 HK HK15109786.2A patent/HK1210495A1/xx unknown
-
2018
- 2018-07-02 CY CY20181100689T patent/CY1120384T1/el unknown
-
2020
- 2020-07-07 CY CY20201100625T patent/CY1123503T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11913000B2 (en) | Aptamer therapeutics useful in the treatment of complement-related disorders | |
| DK2860251T3 (da) | Aptapmer-lægemidler nyttige ved behandling af komplement-relaterede lidelser | |
| AU2012254935B2 (en) | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders | |
| AU2014218429B2 (en) | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders |